Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Rasha Youssef Hagag, Ahmed Fawzy Selim, Omneya Mohamed Darrag, Hassan Zied & Mohamed Sabry Aboelnasr. (2022) Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?. Diabetes, Metabolic Syndrome and Obesity 15, pages 1261-1268.
Read now
Read now
María E. Cárdaba-García, Encarnación Abad-Lecha & Miguel Á. Calleja-Hernández. (2021) Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment. Libyan Journal of Medicine 16:1.
Read now
Read now
Articles from other publishers (20)
Diego Casas-Deza, Ana Martínez-Sapiña, Silvia Espina, Beatriz Garcia-Rodriguez, Eva M. Fernandez-Bonilla, Alejandro Sanz-Paris, Yolanda Gonzalez-Irazabal, Vanesa Bernal-Monterde & Jose M. Arbones-Mainar. (2022) Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Naïve Patients without History of Cardiovascular Disease. Journal of Clinical Medicine 11:14, pages 4049.
Crossref
Crossref
Nehal K. Abdel Fattah, Sara M. Shaheen, Osama A. Ahmed, Kadry Elsaeed & Nagwa A. Sabri. (2022) Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals. F1000Research 11, pages 649.
Crossref
Crossref
Tarek Yosef, Wesam Ahmed Ibrahim, Ahmed El-Ghandour, Soha Attia & Sarah El-Nakeep. (2021) Effect of different direct-acting antiviral regimens for treatment of nondiabetic hepatitis C virus–infected Egyptian patients on insulin resistance and sensitivity. The Egyptian Journal of Internal Medicine 33:1.
Crossref
Crossref
Amira Isaac, Basant Elmarashly, Kadry El Saeed, Rasha Samir Mohamed, Shereen Abdelmonem Ibrahim & Eslam Safwat. (2021) The effect of hepatitis C virologic clearance on cardiovascular disease biomarker lipoprotein-associated phospholipase A2 and its relation to serum lipids. Egyptian Liver Journal 11:1.
Crossref
Crossref
Fariborz Mansour-Ghanaei, Farahnaz Joukar, Mohammadreza Naghipour, Soheil Hassanipour, Sara Yeganeh, Masood Sepehrimanesh & Mohammad Fathalipour. (2021) Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS). BMC Research Notes 14:1.
Crossref
Crossref
Mahmoud Abdo, Ahmed Rabiee, Zeinab Abdellatif, Shereen Abdel Alem & Ahmed Moustafa. (2020) Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir. European Journal of Gastroenterology & Hepatology 33:12, pages 1588-1594.
Crossref
Crossref
Noriyuki Akutsu, Shigeru Sasaki, Takeshi Matsui, Hirofumi Akashi, Kazuhiko Yonezawa, Keisuke Ishigami, Masayuki Tsujisaki, Hiroyuki Isshiki, Atsushi Yawata, Satoshi Yamaoka, Toshihiro Ban, Takeya Adachi, Seiya Nakahara, Hideyasu Takagi, Kohei Nakachi, Katsunori Tanaka, Takehiro Hirano, Itaru Yamamoto, Hiroyuki Kaneto, Kohei Wagatsuma, Yasunao Numata & Hiroshi Nakase. (2021) Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment. Internal Medicine 60:21, pages 3369-3376.
Crossref
Crossref
Cheng‐Heng Lin, Jyh‐Jou Chen, Pei‐Lun Lee, Hung‐Da Tung, Chun‐Ta Cheng, Hsu‐Ju Kao, Yu‐Hsun Wu, Mai‐Gio Pang & Tang‐Wei Chuang. (2020) Lipid profile changes after direct acting antiviral treatment in different genotypes of chronic hepatitis C virus‐infected patients. Advances in Digestive Medicine 8:3, pages 139-145.
Crossref
Crossref
Tiffany Khoo, Danielle Lam & John K Olynyk. (2021) Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. World Journal of Gastroenterology 27:29, pages 4831-4845.
Crossref
Crossref
Rosanna Villani, Francesca Di Cosimo, Antonino Davide Romano, Moris Sangineto & Gaetano Serviddio. (2021) Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis. Scientific Reports 11:1.
Crossref
Crossref
Ahmed Farouk Alaarag, Ahmed Mohamed Hamam & Osama Ahmed Amin. (2021) The Safety of The Directly Acting Antiviral Treatment For Hepatitis C Virus According To The Egyptian National Program Protocol In Patients With Midrange Ejection Fraction. Global Heart 16:1.
Crossref
Crossref
Riccardo Nevola, Luca Rinaldi, Letizia Zeni, Ferdinando C Sasso, Pia C Pafundi, Barbara Guerrera, Aldo Marrone, Mauro Giordano & Luigi E Adinolfi. (2020) Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals. JGH Open 4:4, pages 713-721.
Crossref
Crossref
Silvia Goñi Esarte, Regina Juanbeltz, José Manuel Zozaya, Juan Isidro Úriz, Jesús Castilla & José Ignacio Herrero. (2020) Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. Gastroenterología y Hepatología 43:5, pages 248-255.
Crossref
Crossref
Silvia Goñi Esarte, Regina Juanbeltz, José Manuel Zozaya, Juan Isidro Úriz, Jesús Castilla & José Ignacio Herrero. (2020) Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. Gastroenterología y Hepatología (English Edition) 43:5, pages 248-255.
Crossref
Crossref
M.A. Shawky, A.Q. Mohammed, A.M. Hassan, B.H. Ali & H.M. Moustafa. (2020) Insulin resistance in nondiabetic Egyptian patients with chronic hepatitis C virus. Revista de Gastroenterología de México (English Edition) 85:2, pages 173-179.
Crossref
Crossref
M.A. Shawky, A.Q. Mohammed, A.M. Hassan, B.H. Ali & H.M. Moustafa. (2020) Resistencia a la insulina en pacientes egipcios no diabéticos infectados con el virus de hepatitis C crónica. Revista de Gastroenterología de México 85:2, pages 173-179.
Crossref
Crossref
Francesco Paolo Russo, Alberto Zanetto, Martina Gambato, Ilaria Bortoluzzi, Ramona Al Zoairy, Enrica Franceschet, Federica De Marchi, Luca Marzi, Erica Nicola Lynch, Annarosa Floreani, Fabio Farinati, Benedikt Schaefer, Patrizia Burra, Heinz Zoller & Andrea Mega. (2019) Hepatitis C virus eradication with direct‐acting antiviral improves insulin resistance. Journal of Viral Hepatitis 27:2, pages 188-194.
Crossref
Crossref
Evangelista Sagnelli, Caterina Sagnelli, Antonio Russo, Mariantonietta Pisaturo, Clarissa Camaioni, Roberta Astorri & Nicola Coppola. 2021. Advances in Microbiology, Infectious Diseases and Public Health. Advances in Microbiology, Infectious Diseases and Public Health
115
147
.
Mostafa Elhelbawy, Wael Abdel-Razek, Ayman Alsebaey, Mohamed Hashim, Hassan Elshenawy & Imam Waked. (2019) Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. European Journal of Gastroenterology & Hepatology 31:1, pages 16-23.
Crossref
Crossref
Sylvia Drazilova, Jakub Gazda, Martin Janicko & Peter Jarcuska. (2018) Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Canadian Journal of Gastroenterology and Hepatology 2018, pages 1-11.
Crossref
Crossref